Premium
Paediatric patients with inflammatory bowel disease who received infliximab experienced improved growth and bone health
Author(s) -
Pichler Judith,
Hanslik Andreas,
Dietrich Huber Wolf,
Aufricht Christoph,
BidmonFliegenschnee Bettina
Publication year - 2014
Publication title -
acta paediatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/apa.12448
Subject(s) - medicine , infliximab , bone mineral , inflammatory bowel disease , anthropometry , body mass index , bone health , gastroenterology , surgery , pediatrics , disease , osteoporosis
Abstract Aim Children with inflammatory bowel disease ( IBD ) have a high prevalence of growth retardation and low bone mineral density ( BMD ). This retrospective study investigated whether the start of infliximab treatment ( IFX ) was associated with improvement of growth and bone health. Methods Anthropometry, BMD and bone markers were measured 1 year before and after the start of IFX treatment in 33 patients (51% males), with a median age of 13.5 years at baseline. Outcomes were growth with treatment and indicators of improved bone health. Results Twenty‐one children (64%) experienced a positive catch‐up growth after IFX . Height standard deviation scores ( SDS ) were significantly higher in children in remission. Treatment with IFX was associated with a statistically significant increase in 25‐hydroxycholecalciferol (25‐ OHD , p = 0.01). IFX had no influence on BMD . Children with low BMD < −2 had significantly higher inflammation scores, lower body mass index, weight, height SDS and 25‐ ODH after IFX . Conclusion After treatment with IFX , children with IBD improved significantly in weight, with the majority achieving positive catch‐up growth. Bone mass tended to remain static with time of treatment with IFX , despite a significant increase in 25‐ OHD . Improved nutritional status positively predicts improved bone mineralisation.